Egetis Therapeutics to Explore Tiratricol (Emcitate®) for Resistance to Thyroid Hormone Beta (RTHβ)
核心洞察
Egetis Therapeutics (搜索) will investigate tiratricol (Emcitate®) for Resistance to Thyroid Hormone beta (搜索) (RTHβ (搜索)), a rare genetic disorder with no approved treatments.
A multicenter, investigator-initiated Phase 2 study in RTHβ (搜索) patients is being contemplated in collaboration with academia, leveraging tiratricol's Orphan Drug Designations.
RTHβ (搜索) affects 1-2 individuals per 40,000 live births and results in impaired thyroid hormone signaling, leading to a mix of thyrotoxicosis and hypothyroidism symptoms.
Egetis Therapeutics (搜索) AB (publ) (Nasdaq Stockholm: EGTX) has announced its decision to explore tiratricol (Emcitate®) as a potential treatment for Resistance to Thyroid Hormone beta (搜索) (RTHβ (搜索)). The company is considering supporting a multicenter, investigator-initiated Phase 2 study in collaboration with academic partners.
RTHβ (搜索) is a rare genetic disorder characterized by impaired thyroid hormone signaling due to mutations in the thyroid hormone receptor beta (搜索) gene. This condition affects an estimated 1-2 individuals per 40,000 live births and currently has no approved treatments, representing a significant unmet medical need. Thyroid hormone, crucial for tissue development and metabolic regulation, acts through nuclear thyroid hormone receptors, influencing the transcription of hormone-responsive genes. RTHβ disrupts this process, leading to a combination of thyrotoxicosis and hypothyroidism symptoms across different tissues.
Clinical Manifestations and Disease Burden
Clinical manifestations of RTHβ (搜索) include goiter, hepatic steatosis, dyslipidemia, impaired hearing and color vision, neurocognitive dysfunction, and cardiovascular stress. Recent studies have highlighted the severity of the condition, demonstrating that patients with RTHβ experience reduced survival and increased cardiovascular morbidity. Okosieme et al. (2023) and Campi et al. (2024) have published data underscoring these risks, emphasizing the need for effective therapeutic interventions.
Tiratricol (Emcitate®) and RTHβ
Tiratricol (Emcitate®) has received Orphan Drug Designation for RTHβ (搜索) in both the USA and EU. This regulatory status underscores the potential of tiratricol to address this rare and serious condition. It is important to note that RTHβ is a distinct indication from MCT8 (搜索) deficiency, with no overlap in patient populations. Egetis Therapeutics (搜索) is also developing tiratricol for MCT8 deficiency.
Future Development Plans
Egetis Therapeutics (搜索) plans to share further details on the specific development plans for tiratricol in RTHβ (搜索) after finalization. An RTHβ presentation and unmet medical need will be given at Egetis’ Investor Day on December 18, 2024.
Nicklas Westerholm, CEO of Egetis Therapeutics (搜索), and Karl Hård, Head of Investor Relations & Business Development, are available for further inquiries regarding this development.